| Name | (E/Z)-Teriflunomide |
| Description | (E/Z)-Teriflunomide (Aubagio), a orally-available Pyrimidine Synthesis Inhibitor, is used to treat relapsing multiple sclerosis. |
| In vitro | In animal models of demyelinating diseases, Teriflunomide has demonstrated efficacy. For instance, in the black rat model of autoimmune encephalomyelitis, Teriflunomide has shown both preventive and therapeutic effects; similarly, in female Lewis rat models of Experimental Autoimmune Encephalomyelitis (EAE), it has been effective in ameliorating symptoms and reducing disease exacerbation. |
| In vivo | Teriflunomide acts as a dihydroorotate dehydrogenase inhibitor, thereby inhibiting the de novo synthesis of pyrimidine in rapidly proliferating cells. By suppressing highly proliferative T and B lymphocytes, Teriflunomide effectively reduces the inflammatory response to self-antigens. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.25 mg/mL (23.13 mM), Sonication is recommended.
|
| Keywords | Teriflunomide | HMR1726 | HMR 1726 | Dihydroorotate Dehydrogenase | (E/Z)-Teriflunomide |
| Inhibitors Related | Disulfiram | Mycophenolate Mofetil | Rotenone | Ribavirin | 18β-Glycyrrhetinic acid | Benzyl alcohol | 2-Methylaminoethanol | Methotrexate disodium | Dimethyl malonate | Isomalt | D-Mannitol | Ethyl potassium malonate |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pediatric Drug Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |